amuvatinib + paclitaxel + carboplatin

Amuvatinib (MP-470) is an orally bioavailable, synthetic small molecule that acts as a multi-targeted tyrosine kinase inhibitor. It inhibits mutant and wild-type forms of c-Kit, PDGFRα, Flt3, c-Met, RET proto-oncogene, AXL receptor tyrosine kinase, and the DNA repair protein Rad51 recombinase. By blocking these kinases and interfering with DNA repair mechanisms in cancer cells, amuvatinib exhibits antineoplastic activity and can potentiate the effects of DNA-damaging agents such as chemotherapy. Amuvatinib has been studied in combination with standard chemotherapeutic agents like paclitaxel (a microtubule stabilizer) and carboplatin (a platinum-based DNA crosslinker), particularly for solid tumors including small cell lung carcinoma. The combination aims to enhance tumor cell death by targeting multiple pathways involved in tumor growth and resistance[1][2][4][5][8].

Other names

amuvatinib